Katharine Spink

Katharine (Katy) Spink is an accomplished leader in the biotechnology sector, currently serving as President & COO, Managing Partner, and Board Director at Dark Horse Consulting Group Inc., a firm specializing in Cell and Gene Therapy product development since January 2018. In addition, Spink holds board positions at MicrofluidX and Single Use Support GmbH and chairs the CMC and Commercialization Committees of the American Society of Gene & Cell Therapy. Previously, Spink was Chief Operating Officer at Asterias Biotherapeutics, where responsibilities included comprehensive program management and business development. With expertise rooted in a Ph.D. in Cancer Biology from Stanford University School of Medicine and extensive experience in various roles at Geron Corporation and McKinsey & Company, Spink has a proven track record in operational leadership, strategic planning, and alliance management within the biotechnology industry.